Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ) is a China-based pharmaceutical manufacturer and R&D company under Sino Biopharmaceutical Limited. It develops, produces, and markets prescription medicines and active pharmaceutical ingredients (APIs), with core therapeutic focuses in hepatology, oncology, respiratory diseases, cardiovascular conditions, and anti-infectives.
CTTQ operates GMP-compliant facilities and integrated R&D and manufacturing capabilities spanning process development, API synthesis, and finished dosage forms such as injectables and oral solids. The company serves the domestic Chinese market and selected international markets through a portfolio that includes innovative and generic small‑molecule drugs, supported by clinical development and pharmacovigilance systems. Its operations are centered in Jiangsu Province, China.
Also known as CTTQ.
Potential first-in-class CHB treatment under priority review in China; deal provides access to 5,000+ medical centres at launch, local import/distribution, hospital access and initial 5.5-yr supply.
